189 related articles for article (PubMed ID: 3261622)
1. Positron emission tomography in patients with glioma. A predictor of prognosis.
Alavi JB; Alavi A; Chawluk J; Kushner M; Powe J; Hickey W; Reivich M
Cancer; 1988 Sep; 62(6):1074-8. PubMed ID: 3261622
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma.
De Witte O; Levivier M; Violon P; Salmon I; Damhaut P; Wikler D; Hildebrand J; Brotchi J; Goldman S
Neurosurgery; 1996 Sep; 39(3):470-6; discussion 476-7. PubMed ID: 8875476
[TBL] [Abstract][Full Text] [Related]
3. Brain imaging of glucose utilization in cerebral tumors.
Di Chiro G
Res Publ Assoc Res Nerv Ment Dis; 1985; 63():185-97. PubMed ID: 3875134
[No Abstract] [Full Text] [Related]
4. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma.
Barker FG; Chang SM; Valk PE; Pounds TR; Prados MD
Cancer; 1997 Jan; 79(1):115-26. PubMed ID: 8988735
[TBL] [Abstract][Full Text] [Related]
5. Changes in glucose uptake by malignant gliomas: preliminary study of prognostic significance.
Rozental JM; Levine RL; Nickles RJ
J Neurooncol; 1991 Feb; 10(1):75-83. PubMed ID: 2022974
[TBL] [Abstract][Full Text] [Related]
6. Effect of barbiturate coma on glucose utilization in normal brain versus gliomas. Positron emission tomography studies.
Blacklock JB; Oldfield EH; Di Chiro G; Tran D; Theodore W; Wright DC; Larson SM
J Neurosurg; 1987 Jul; 67(1):71-5. PubMed ID: 3496428
[TBL] [Abstract][Full Text] [Related]
7. Independent thallium-201 accumulation and fluorine-18-fluorodeoxyglucose metabolism in glioma.
Oriuchi N; Tomiyoshi K; Inoue T; Ahmad K; Sarwar M; Tokunaga M; Suzuki H; Watanabe N; Hirano T; Horikoshi S; Shibasaki T; Tamura M; Endo K
J Nucl Med; 1996 Mar; 37(3):457-62. PubMed ID: 8772644
[TBL] [Abstract][Full Text] [Related]
8. Uncoupling of hexose transport and phosphorylation in human gliomas demonstrated by PET.
Herholz K; Ziffling P; Staffen W; Pawlik G; Wagner R; Wienhard K; Heiss WD
Eur J Cancer Clin Oncol; 1988 Jul; 24(7):1139-50. PubMed ID: 3262062
[TBL] [Abstract][Full Text] [Related]
9. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography.
Di Chiro G; DeLaPaz RL; Brooks RA; Sokoloff L; Kornblith PL; Smith BH; Patronas NJ; Kufta CV; Kessler RM; Johnston GS; Manning RG; Wolf AP
Neurology; 1982 Dec; 32(12):1323-9. PubMed ID: 6983044
[TBL] [Abstract][Full Text] [Related]
10. New grading system of cerebral gliomas using positron emission tomography with F-18 fluorodeoxyglucose.
Kim CK; Alavi JB; Alavi A; Reivich M
J Neurooncol; 1991 Feb; 10(1):85-91. PubMed ID: 2022975
[TBL] [Abstract][Full Text] [Related]
11. Perfusion and metabolism in predicting the survival of patients with cerebral gliomas.
Mineura K; Sasajima T; Kowada M; Ogawa T; Hatazawa J; Shishido F; Uemura K
Cancer; 1994 May; 73(9):2386-94. PubMed ID: 8168042
[TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool.
Di Chiro G
Invest Radiol; 1987 May; 22(5):360-71. PubMed ID: 3496318
[No Abstract] [Full Text] [Related]
13. EEG, transmission computed tomography, and positron emission tomography with fluorodeoxyglucose 18F. Their use in adults with gliomas.
Newmark ME; Theodore WH; Sato S; De La Paz R; Patronas N; Brooks R; Jabbari B; Di Chiro G
Arch Neurol; 1983 Oct; 40(10):607-10. PubMed ID: 6615267
[TBL] [Abstract][Full Text] [Related]
14. Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) of brain tumors.
Rozental JM
Neurol Clin; 1991 May; 9(2):287-305. PubMed ID: 1944100
[TBL] [Abstract][Full Text] [Related]
15. The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using 18F-fluorodeoxyglucose and 11C-L-methylmethionine.
Derlon JM; Petit-Taboué MC; Chapon F; Beaudouin V; Noël MH; Creveuil C; Courtheoux P; Houtteville JP
Neurosurgery; 1997 Feb; 40(2):276-87; discussion 287-8. PubMed ID: 9007859
[TBL] [Abstract][Full Text] [Related]
16. Impact of fluorodeoxyglucose positron emission tomography on the clinical management of patients with glioma.
Deshmukh A; Scott JA; Palmer EL; Hochberg FH; Gruber M; Fischman AJ
Clin Nucl Med; 1996 Sep; 21(9):720-5. PubMed ID: 8879874
[TBL] [Abstract][Full Text] [Related]
17. In vivo imaging of glucose consumption and lactate concentration in human gliomas.
Herholz K; Heindel W; Luyten PR; denHollander JA; Pietrzyk U; Voges J; Kugel H; Friedmann G; Heiss WD
Ann Neurol; 1992 Mar; 31(3):319-27. PubMed ID: 1637139
[TBL] [Abstract][Full Text] [Related]
18. FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma.
Hölzer T; Herholz K; Jeske J; Heiss WD
J Comput Assist Tomogr; 1993; 17(5):681-7. PubMed ID: 8370819
[TBL] [Abstract][Full Text] [Related]
19. Relation between tissue nature and (18F) fluorodeoxyglucose kinetics evaluated by dynamic positron emission tomography in human brain tumors.
Yamaguchi T; Sasaki H; Ogawa T; Mineura K; Uemura K; Kanno I; Shishido F; Murakami M; Inugami A; Higano S
Acta Radiol Suppl; 1986; 369():415-8. PubMed ID: 2980513
[TBL] [Abstract][Full Text] [Related]
20. [An analysis of 18FDG kinetic rate constants using dynamic positron emission tomography in human brain tumors].
Yamaguchi T; Sasaki H; Uemura K; Shishido F; Inugami A; Ogawa T; Higano S; Mineura K; Kanno I; Murakami M
Kaku Igaku; 1986 Jun; 23(6):829-32. PubMed ID: 3489854
[No Abstract] [Full Text] [Related]
[Next] [New Search]
